However, many side effects such as thrombotic microangiopathy in animal experiments and increased mortality in myocardial infarction (MI) patients have been reported [22, 23], and the therapy also interferes with the physiological effects of VEGF like balancing the survival, integrity, and maintenance of the homeostasis of choroidal endothelial cells [24, 25]. The gene discussed is VEGFA; the disease is myocardial infarction.